James Lynch, CEO

James Lynch is a seasoned pharmaceutical executive with over 30 years of experience in drug development, corporate strategy, and biotech leadership. As CEO of DNA Nanobots, he guides the company’s mission to transform non-viral gene delivery through DNA origami technology.

Previously, James served as CEO of Nanopharmaceuticals Inc., where he led a glioblastoma therapy from preclinical to Phase I trials, securing $4.1M in funding. His leadership history spans companies like Rockwell Medical, Quintiles, and Reliant Pharmaceuticals, with a focus on strategic partnerships, clinical advancement, and global commercialization.

With a track record of driving biotech innovation, James brings deep expertise in oncology, gene therapy, and rare diseases. His vision and business acumen position DNA Nanobots to lead in next-generation therapeutics.